Safety and Efficacy of Ceftazidime/Avibactam in the Treatment of Severe Neonatal Infections
OBJECTIVES: Epidemiological data from China indicates a higher proportion of metallo lactamase produced by Escherichia coli and Klebsiella pneumoniae in pediatric patients compared to adults. Ceftazidime/avibactam (CAZ/AVI), a broad-spectrum antibacterial drug. The efficacy and safety of CAZ/AVI com...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716524003990 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | OBJECTIVES: Epidemiological data from China indicates a higher proportion of metallo lactamase produced by Escherichia coli and Klebsiella pneumoniae in pediatric patients compared to adults. Ceftazidime/avibactam (CAZ/AVI), a broad-spectrum antibacterial drug. The efficacy and safety of CAZ/AVI combined with aztreonam(ATM) in treating metallo lactamase producing CRE infections have been established. The recent introduction of Aztreonam/Avibactam in Europe is noteworthy. However, there remains limited evidence regarding the safety and efficacy of CAZ/AVI in neonatal patients. This study aims to explore the potential benefits of this drug in treating neonatal patients through retrospective analysis METHODS: Retrospective characteristics between January 1, 2022, and December 31, 2023 of patients under 3 months old using the CAZ/AVI in a tertiary children's specialized hospital were collected. RESULTS: A total of 10 patients were treated with CAZ/AVI. All patients had severe underlying diseases such as neonatal respiratory distress and necrotizing colitis. The dosage was administered following the manufacturer's instructions, with 9 cases receiving targeted treatment. 4 patients were infected by producing NDM CRE strains. 8 patients were treated with a combination of ATM, with an average treatment duration of 13.9 days. All patients survived, and no adverse reactions were observed. CONCLUSIONS: CAZ/AVI demonstrates safety profiles in managing severe neonatal infections. The addition of aztreonam has shown to be efficacious and safe in treating CRE strain infections. While the recommended age limit for administration is currently set at over 3 months, it may be considered as a viable alternative for treating severe or complicated infections in newborns. |
|---|---|
| ISSN: | 2213-7165 |